NEUROONE MEDICAL TECHNOLOGIES Corp · Surgical & Medical Instruments & Apparatus

NMTC

High riskNext report: Around Dec 16 (est.)

View price ↗

The short version

A company still losing money with growing sales, with elevated risk.

Going well

Sales up 16% in the latest quarter vs a year ago
Sales up 164% last year
No debt reported

Watch out for

About 15 months of cash left at its current burn
Share count growing 35.9% a year (dilution)
Losing money, losses are large next to sales

Money moves

No insider buying or selling in the last 30 days

Facts from SEC filings, not a recommendation.

What the price means

Price as of Oct 26

$0.80-9.1% that day

Company value: $7M; Share price times all shares
Price vs profit (P/E): 1.3x; You pay about $1 for each $1 of yearly profit
Price vs sales: 0.77x; Company value is 0.77 times a year of sales
Cash vs value: 28%; Cash as a share of company value

From NMTC's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.

The business over time

Last 12 quarters, from SEC filings

Sales, Jun '26

$2.0M+16% vs a year earlier

Sep '23Tap a barJun '26

Last 12 months: $9.5M, up 43% from the 12 months before.

What the price assumes

Your guesses, our math

Move the sliders to your own view of NMTC. Starting points are the company's recent numbers (it isn't profitable yet, so the margin starts at a 10% guess).

Sales growth+30% a yearRecently: +43% a yearProfit margin10%Last 12 months: -78.6%P/E at the end8xToday: 1.3x. Many steady companies trade at 12x to 25xShare count change+10% a yearBelow zero means buybacks; above zero means new shares (dilution)

Sales in 5 years$35M

Profit in 5 years$4M

Price these guesses point to$1.92+140% vs $0.80 todayAbout +19% a year, before dividends

What today's price needs: with a 10% margin and a 8x P/E, sales would have to grow about 9.1% a year for 5 years just to match today's price.

Simple math on your guesses, not a forecast or a price target. Real results depend on many things these sliders leave out.

Price

Price chart by TradingView.

Business quality

The checklist Warren Buffett-style investors use. Annual numbers for 2025.

2/7Weak

MissReturn on equity 15%+Earns a lot on the money owners have in the business.-77.2%
PassDebt under half of equityNot relying on borrowed money.No debt reported
MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.-39.6%
MissProfitable every yearSteady profits, not one good year.0 of 9 years
MissFree cash flow positiveBrings in more cash than it spends to run and grow.-$2.9M
MissShare count not growingNot diluting owners. Falling means buybacks.+151.0% in 3 years
PassGross margin 40%+Pricing power: sells for well above what it costs to make.56.5%

Revenue: $9.1M; +163.5% vs prior year
Total debt: None; 0.00x equity
Current ratio: 6.41x; short-term assets / bills due
Free cash flow: -$2.9M; -32.1% of revenue

From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.

Latest quarter

Quarter ended Jun 30, 2026

Reported Oct 5

Revenue: $2.0M; +16.3% YoY
EPS: -$0.28; vs -$1.14
Op. margin: -122.9%; -11.7 pts
Gross margin: 59.9%; +6.0 pts
Free cash flow: -$1.1M
Share count: +547.3%; vs a year ago

Insider rating

Last 90 days

No open-market insider buys or sells in the last 90 days.

Weekly insider trend

No trades to chart yet.

Filing buzz

Last 7 days vs normal

0/ 100

This week: 0
Normal week: 0.8
vs normal: 0.0x

SEC filings of any kind. 50 means a normal week.

Institutional ownership

Newly held

Institutions held almost none of it the quarter before (new listing, spin-off or ticker change), so there's no fair percent change yet. 24 bought, 1 sold.

Shares held by institutions2.1M

Sep '24Jun '26